Duffy Michael J, Duggan Catherine, Keane Rachel, Hill Arnold D K, McDermott Enda, Crown John, O'Higgins Niall
Department of Nuclear Medicine, St. Vincent's University Hospital, Dublin, Ireland.
Clin Chem. 2004 Mar;50(3):559-63. doi: 10.1373/clinchem.2003.025288. Epub 2004 Jan 15.
CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease.
Preoperative CA 15-3 concentrations were measured prospectively in 600 patients with histologically confirmed breast cancer. Marker concentrations were related to patient outcome by both univariate and multivariate analysis.
After a median follow-up of 6.27 years, patients with high preoperative concentrations of CA 15-3 (>30 units/L) had a significantly shorter overall survival pattern than those with low concentrations. As a prognostic factor, CA 15-3 was independent of tumor size, axillary node status, and patient age. As well as being prognostic in the total population of patients, CA 15-3 also predicted outcome in different subgroups of patients, including those with both node-negative and node-positive disease, those who were both estrogen receptor (ER)-negative and ER-positive, and those younger and older that 50 years of age. CA 15-3 was also predictive of outcome irrespective of the type of adjuvant therapy administered, i.e., whether adjuvant hormone therapy, adjuvant chemotherapy, or radiotherapy was administered.
Assay of CA 15-3 is a relatively inexpensive, convenient, and noninvasive method for evaluating prognosis in newly diagnosed breast cancer patients.
CA 15-3是乳腺癌中使用最广泛的血清标志物。目前，其主要用途是对已确诊疾病的患者进行监测以及对晚期疾病患者的治疗进行监测。
前瞻性地测量了600例经组织学确诊为乳腺癌患者的术前CA 15-3浓度。通过单因素和多因素分析将标志物浓度与患者预后相关联。
中位随访6.27年后，术前CA 15-3浓度高（>30单位/升）的患者总生存模式明显短于浓度低的患者。作为一个预后因素，CA 15-3独立于肿瘤大小、腋窝淋巴结状态和患者年龄。除了在患者总体人群中具有预后价值外，CA 15-3还能预测不同亚组患者的预后，包括淋巴结阴性和阳性疾病患者、雌激素受体（ER）阴性和阳性患者以及年龄小于和大于50岁的患者。无论给予何种辅助治疗类型，即是否给予辅助激素治疗、辅助化疗或放疗，CA 15-3均能预测预后。
检测CA 15-3是评估新诊断乳腺癌患者预后的一种相对廉价、方便且无创的方法。
